Showing results (41-50 of 1,111) with videos related to
Sort By:
Pageof 112
Journal of Hepatology|September 20, 2012
Factor VII activating protease (FSAP) exerts anti-inflammatory and anti-fibrotic effects in liver fibrosis in mice and menErawan Borkham-Kamphorst, Henning W Zimmermann, Nikolaus Gassler, et al.Materials Science & Engineering. C, Materials for Biological Applications|April 6, 2015
Molecular response of liver sinusoidal endothelial cells on hydrogelsMatthias Bartneck, Fuat Topuz, Carmen Gabriele Tag, et al.Mediators of Inflammation|August 13, 2013
Regulation and prognostic relevance of symmetric dimethylarginine serum concentrations in critical illness and sepsisAlexander Koch, Ralf Weiskirchen, Jan Bruensing, et al.Journal of Critical Care|August 20, 2013
Elevated asymmetric dimethylarginine levels predict short- and long-term mortality risk in critically ill patientsAlexander Koch, Ralf Weiskirchen, Julian Kunze, et al.Journal of Critical Care|September 14, 2016
Relevance of serum sclerostin concentrations in critically ill patientsAlexander Koch, Ralf Weiskirchen, Sebastian Ludwig, et al.Fibrogenesis & Tissue Repair|November 27, 2013
Experimental liver fibrosis research: update on animal models, legal issues and translational aspectsChristian Liedtke, Tom Luedde, Tilman Sauerbruch, et al.Journal of Cellular and Molecular Medicine|April 19, 2011
From proteomic multimarker profiling to interesting proteins: thymosin-β(4) and kininogen-1 as new potential biomarkers for inflammatory hepatic lesionsCorinna Henkel, Kristina Schwamborn, Henning W Zimmermann, et al.Cellular and Molecular Gastroenterology and Hepatology|September 8, 2020
Roles of CCR2 and CCR5 for Hepatic Macrophage Polarization in Mice With Liver Parenchymal Cell-Specific NEMO DeletionMatthias Bartneck, Christiane Koppe, Viktor Fech, et al.Disease Markers|September 19, 2018
Visfatin Serum Levels Predict Mortality in Critically Ill PatientsAlexander Koch, Ralf Weiskirchen, Alexander Krusch, et al.Medical Sciences (Basel, Switzerland)|November 24, 2025
Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver DisordersRalf Weiskirchen, Amedeo LonardoPageof 112